Inotropic Stimulation and Myocardial Energetics

Chapter 1 Introduction: Mechanisms of positive inotropic effects

Chapter 2 Adrenoceptors in myocardial regulation: concomitant contribution from both alpha- and beta-adrenoceptor stimulation to the inotropic response

Chapter 3 Studies on the cellular mechanisms of action of positive and negative inotropic agents

Chapter 4 On the mechanism of positive inotropic effects of alpha-adrenoceptor agonists

Chapter 5 Cytosolic sodium concentration regulates contractility of cardiac muscle

Chapter 6 Energy requirements of contraction and relaxation: implications for inotropic stimulation of the failing heart

Chapter 7 Genetic and non-genetic control of myocardial calcium

Chapter 8 Regulation of force and intracellular calcium transients by cyclic AMP generated by forskolin, MDL 17,043 and isoprenaline, and its modulation by muscarinic receptor agents: a novel mechanism for accentuated antagonism

Chapter 9 Studies on the mechanism of action of the bipyridine milrinone on the heart

Chapter 10 Ca-Agonists: a new class of inotropic drugs

Chapter 11 Myofibrillar Ca+ + activation and heart failure — Ca+ + sensitization by the cardiotonic agent APP 201–533

Chapter 12 Positive inotropic stimulation in the normal and insufficient human myocardium

Chapter 13 Do human cardiac beta-2 adrenoceptors play a (patho)physiological role in regulation of heart rate and/or contractility?

Chapter 14 Influence of isoproterenol on myocardial energetics. Experimental and clinical investigations

Chapter 15 Effects of long-term xamoterol therapy on the left ventricular mechanical efficiency in patients with ischemic heart disease

Chapter 16 Modulation of the autonomic control of the failing heart

Chapter 17 Dopexamine in congestive heart failure: how do the pharmacological activities translate into the clinical situation?

Chapter 18 The use of levodopa, an oral dopamine precursor, in congestive heart failure

Chapter 19 Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure

Chapter 20 Cardiovascular effects of forskolin and phosphodiesterase-III inhibitors

Chapter 21 Phosphodiesterase inhibitors: alterations in systemic and coronary hemodynamics

Chapter 22 Influence of the calcium-sensitizer UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Comparison with nitroprusside

Chapter 23 Myocardial energetics: experimental and clinical studies to address its determinants and aerobic limit

Chapter 24 Use of a conductance catheter to detect increased left ventricular inotropic state by end-systolic pressure-volume analysis

Chapter 25 Separation between vasodilation and positive inotropism by assessment of myocardial energetics in patients with dilated cardiomyopathy